SEC Filing Document

Company: BIOVENTRIX, INC.
Ticker: 
CIK: 1283259
Filing Type: S-1/A
Document Type: EX-3.10
Date Filed: 2026-05-15
Accession Number: 0001493152-26-023752
Exchange: 
SIC Code: 3841
SIC Description: Surgical & Medical Instruments & Apparatus
URL: https://www.sec.gov/Archives/edgar/data/1283259/000149315226023752/ex3-10.htm

Chunk 0 of 5
Word Count: 1436
Character Count: 8810

Document Content:

Exhibit

CERTIFICATE
OF DESIGNATIONS OF

THE
RIGHTS, PREFERENCES AND PRIVILEGES OF THE

SERIES
A-2 PREFERRED STOCK OF BIOVENTRIX, INC.

Pursuant
to Sections 103 and 151of

The
General Corporation Law of the State of Delaware

Bioventrix,
Inc. (the “ Corporation”), a corporation organized and existing under the laws of the State of Delaware,
DOES HEREBY CERTIFY:

FIRST:
The Corporation’s Third Amended and Restated Certificate of Incorporation of the Corporation was filed with the Secretary of State
of the State of Delaware on March 29, 2023, which as amended by the First Amendment to the Third Amended and Restated Certificate of
Incorporation that was filed with the Secretary of State of the State of Delaware on January 16, 2024 and further amended by the Second
Amendment to the Third Amended and Restated Certificate of Incorporation that was filed with the Secretary of State of the State of Delaware
on August 14, 2024 and further amended by the Third Amendment to the Third Amended and Restated Certificate of Incorporation that was
filed with the Secretary of State of the State of Delaware on August 1, 2025 (the “Restated Certificate”).

SECOND:
Article Fourth B. of the Restated Certificate authorizes the Board of Directors of the Corporation (the “ Board”)
to determine, by resolutions duly adopted by the Board, the issuance of the remaining unissued and undesignated shares of Preferred Stock
in one or more classes or series, and to fix for each such powers, preferences, privileges and rights and such qualifications, limitations
or restrictions thereof, as shall be stated and expressed in the resolutions adopted by the Board providing for the issuance of such
class or series and as may be permitted by the Delaware General Corporation Law (the “ DGCL”).

THIRD:
Pursuant to and under the authority granted the Board by Article Fourth B. of the Restated Certificate, the Board duly adopted, pursuant
to a unanimous written consent effective April ____, 2026, resolutions providing for the authorization of 200,000 shares of a new Series
A-2 Preferred Stock from the authorized but undesignated Blank Check Preferred Stock of the Corporation, with the powers, preferences,
privileges and rights and the qualifications, limitations and restrictions as stated in EXHIBIT A attached hereto.

FOURTH:
In accordance with, and pursuant to, Section 103 and 151 of the DGCL, the Board has deemed it in the best interests of the Corporation,
and has authorized and directed the officers of the Corporation, to file with the Delaware Secretary of State this Certificate of Designations
of the Rights, Preferences and Privileges of the Series A-2 Preferred Stock.

WITNESS WHEREOF, the Corporation has caused this Certificate of Designations of the Rights, Privileges and Preferences of the Series
A-2 Preferred Stock to be signed by David Richmond, its President, a duly authorized officer of the Corporation, on April ___, 2026.

David Richmond, Co-CEO

EXHIBIT

STATEMENT
OF RIGHTS, PREFERENCES AND PRIVILEGES OF THE SERIES A-2 PREFEREED STOCK OF BIOVENTRIX, INC.

The
following is a statement of the designation and the rights, preferences and privileges, and the qualifications, limitations or restrictions
thereof in respect of the Series A-2 Preferred Stock of the Corporation.

Dividends.

The
Corporation shall not declare, pay or set aside any dividends on shares of any other class or series of capital stock of the Corporation
(other than dividends on shares of Common Stock payable in shares of Common Stock) unless the holders of the Series A-2 Preferred Stock
then outstanding shall first receive, or simultaneously receive, on a pari passu basis to any dividends that are owed to the holders
of Series A Preferred Stock and to any dividends that are owed to the holders of Series A-1 Preferred Stock as provided in the Restated
Certificate, a dividend on each outstanding share of Series A-2 Preferred Stock in an amount at least equal to (i) in the case of a dividend
on Common Stock or any class or series that is convertible into Common Stock, that dividend per share of Series A-2 Preferred Stock as
would equal the product of (A) the dividend payable on each share of such class or series determined, if applicable, as if all shares
of such class or series had been converted into Common Stock and (B) the number of shares of Common Stock issuable upon conversion of
a share of Series A-2 Preferred Stock, in each case calculated on the record date for determination of holders entitled to receive such
dividend or (ii) in the case of a dividend on any class or series that is not convertible into Common Stock, at a rate per share of Series
A-2 Preferred Stock determined by (A) dividing the amount of the dividend payable on each share of such class or series of capital stock
by the original issuance price of such class or series of capital stock (subject to appropriate adjustment in the event of any stock
dividend, stock split, combination or other similar recapitalization with respect to such class or series) and (B) multiplying such fraction
by an amount equal to the Series A-2 Original Issue Price (as defined below); provided that, if the Corporation declares, pays
or sets aside, on the same date, a dividend on shares of more than one (1) class or series of capital stock of the Corporation, the dividend
payable to the holders of Series A-2 Preferred Stock pursuant to this Section 1 shall be calculated based upon the dividend on
the class or series of capital stock that would result in the highest Series A-2 Preferred Stock dividend. The “Series A-2 Original
Issue Price” shall mean $50.00 per share, subject to appropriate adjustment in the event of any stock dividend, stock split,
combination or other similar recapitalization with respect to the Series A-2 Preferred Stock.

Liquidation, Dissolution or Winding Up; Certain Mergers, Consolidations and Asset Sales.

Preferential Payments to Holders of Series A-2 Preferred Stock. In the event of any voluntary or involuntary liquidation, dissolution
or winding up of the Corporation or Deemed Liquidation Event, the holders of shares of Series A-2 Preferred Stock then outstanding shall
be entitled to be paid out of the assets of the Corporation available for distribution to its stockholders on a pari passu basis with
the holders of shares of Series A Preferred Stock and on a pari passu basis with the holders of Series A-1 Preferred Stock before any
payment shall be made to the holders of Common Stock by reason of their ownership thereof, an amount
per share equal to the greater of (i) two (2.0) times the Series A-2 Original Issue Price, plus any dividends accrued but unpaid thereon,
or (ii) such amount per share as would have been payable had all shares of Series A-2 Preferred Stock been converted into Common Stock
pursuant to Section 4 immediately prior to such liquidation, dissolution, winding up or Deemed Liquidation Event (the amount payable
pursuant to this sentence is hereinafter referred to as the “Series A-2 Liquidation Amount”). If upon any such liquidation,
dissolution or winding up of the Corporation or Deemed Liquidation Event, the assets of the Corporation available for distribution to
its stockholders shall be insufficient to pay the holders of shares of Series A-2 Preferred Stock the full amount to which they shall
be entitled under this Subsection 2.1, the holders of shares of Series A-2 Preferred Stock shall share ratably in any distribution
of the assets available for distribution in proportion to the respective amounts which would otherwise be payable in respect of the shares
held by them upon such distribution if all amounts payable on or with respect to such shares were paid in full. The “Series
A-2 Original Issue Price” shall mean $50.00 per share, subject to appropriate adjustment in the event of any stock dividend,
stock split, combination or other similar recapitalization with respect to the Series A-2 Preferred Stock.

Payments to Holders of Common Stock. In the event of any voluntary or involuntary liquidation, dissolution or winding up of the
Corporation or Deemed Liquidation Event, after the payment of all preferential amounts required to be paid to the holders of shares of
Series A-2 Preferred Stock, the holders of shares of Series A-1 Preferred Stock, and the holders of shares of Series A Preferred Stock,
the remaining assets of the Corporation available for distribution to its stockholders shall be distributed among the holders of shares
of Common Stock, pro rata based on the number of shares held by each such holder.

Deemed Liquidation Events.

Definition. Each of the following events shall be considered a “Deemed Liquidation Event”:

a merger or consolidation in which

(i)	the
Corporation is a constituent party or